Activation of apoptosis pathways by anticancer drugs

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 237-244

  Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; APOPTOSIS; DRUG EFFECT; HUMAN; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS;

EID: 0032612964     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_25     Document Type: Article

References (29)

1. Dive C, Evans CA, Whetton AD. Induction of apoptosis - new targets for cancer chemotherapy. Cancer Biol(1992) 3:417-427
2. Hannun YA. Apoptosis and the Dilemma of Cancer Chemotherapy. Blood (1997) 89, 6: 1845-1853
3. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell ( 1997) 88: 323-331
4. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene (1994) 9: 1799-1805
5. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell ( 1993) 74: 957-967
6. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 Status and the Efficacy of Cancer Therapy in Vivo. Science (1994) 266: 807-810
7. Milner J. DNA damage, p53 and anticancer therapies. Nature Med (1995) 1 (9): 879-880
8. Campana D, Coustan-Smith E, Manabe A, Buschle M, Raimondi SC, Behm FG, Ashmun R, Aricò M, Biondi A, Pui C-H. Prolonged Survival of B-Lineage Acute Lymphoblastic Leukemia Cells Is Accompanied by Overexpression of Bcl-2 Protein. Blood (1993) 81 (4): 1025-1031
9. Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud J-P, Guyotat D. High Expression of Bcl-2 Protein in Acute Myeloid Leukemia Cells Is Associated With Poor Response to Chemotherapy. Blood (1993) 81 (11): 3091-3096
10. Miyashita T, Reed JC. Bcl-2 Oncoprotein blocks Chemotherapy-Induced Apoptosis in a Human Leukemia Cell Line. Blood (1993) 81 (1): 151-157
11. L Is Expressed in Neuroblastoma Cells und Modulates Chemotherapy-induced Apoptosis. Cancer Res (1995) 55: 2576-2582
12. L can confer a multidrug resistance phenotype. Blood (1995) 86 (5): 1903-1910
13. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood (1996) 88 (2): 386-401
14. Hermine O, Haioun C, Lepage E, d'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marollcau J-P, Diebold J, Reyes F, Gaulard P. Prognostic significance of Bcl-2 protein expression in aggressive nonHodgkin's lymphoma. Blood ( 1996) 87: 265-272
15. Coustan-Smith E, Kitanaka A, Pui C-H, McNinch L, Evans WE, Raimondi SC, Behm FG, Aricò M, Campana D. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood (1996) 87 (3): 1140-1146
16. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Nordling S, Reed JC. Reduced expression of pro-apoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res (1995) 55: 4471-4478
17. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dörken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer (1995) 60: 854-859
18. Miyashita T, Reed JC. Tumor Suppressor p53 Is a Direct Transcriptional Activator of the Human bax Gene. Cell (1995) 80: 293-299
19. Nagata S, Golstein P. The Fas death factor. Science (1995) 267: 1449-1456
20. Nagata S. Apoptosis by Death Factor. Cell (1997) 88: 355-365
21. Peter ME, Kischkel FC, Hellbardt S, Chinnaiyan AE, Krammer PH, Dixit VM. CD95 (APO-1/Fas)-associating signalling proteins. Cell Death Diff (1996) 3: 161-170
22. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M, Daniel PT, Knipping E, Westendorp MO, Stricker K, Bäumler C, Hellbardt S, Germer M, Peter ME, Debatin K-M. The role of APO-1 mediated apoptosis in the immune system. Immunol Rev (1994) 142: 175-191
23. Scaffidi C, Fulda S, Li F, Friesen C, Srinivasan A, Tomaselli KJ, Debatin K-M, Krammer PH, Peter ME. Two CD95 Signaling Pathways. EMBO J (1998) 17: 1675-1687
24. Kroemer G. The proto-oncogene bcl-2 and its role in regulating apoptosis. Nat Med (1997) 3, 6: 614-620
25. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin K-M, Fischer A, De Villartay JP. Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity. Science (1995) 268: 1347-1349
26. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ, Puck JM. Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome. Cell (1995) 81: 935-946
27. Drappa J, Vaishnaw AK, Sullivan KE, Chu J-L, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med (1996) 335: 1643-1649
28. Debatin K-M. Disturbances of the CD95 (APO-l/Fas) system in disorders of lymphohematopoietic cells. Cell Death Diff(l996) 3 (2): 185-189
29. Barcena A, Park SW, Banapour B, Muench MO, Mechetner E. Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood (1996) 88 (6): 2013-2025